ITP

Hematology

25 drugs in development·16 companies·2 clinical trials

Drug Pipeline by Phase

Approved(6)

Drug	Company
avatrombopag	GYRE THERAPEUTICS, INC. (GYRE)
contiva	GYRE THERAPEUTICS, INC. (GYRE)
doptelet	AKORN INC (AKRX)
promacta	Novartis AG (NVS)
promacta kit	Novartis AG (NVS)
tavalisse	RIGEL PHARMACEUTICALS INC (RIGL)

Phase 3(6)

Drug	Company
hmpl-523	HUTCHMED (China) Ltd (HMDCF)
ianalumab	Merus N.V. (MRUS)
Ianalumab	Novartis AG (NVS)
mezagitamab	TAKEDA PHARMACEUTICAL CO LTD (TKPHF)
mezagitamab	Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) (TAK)
prn1008	Principia Biopharma Inc. (PRNB)

Phase 2(5)

Drug	Company
budoprutug	Climb Bio, Inc. (CLYM)
sar445088	Sanofi (SNY)
thrombopoietin receptor agonist	Merus N.V. (MRUS)
thrombopoietin receptor agonist	NOVARTIS AG (NVSEF)
thrombopoietin receptor agonist	Novartis AG (NVS)

Early Phase 1(1)

Drug	Company
QT-019C	Filana Therapeutics Inc. (FLNA)

Phase 1/Phase 2(3)

Drug	Company
biological	MOMENTA PHARMACEUTICALS INC (MNTA)
intravenous immunoglobulin	MOMENTA PHARMACEUTICALS INC (MNTA)
m254	MOMENTA PHARMACEUTICALS INC (MNTA)

Phase 4(4)

Drug	Company
Efgartigimod IV	ARGENX SE (ARGX)
efgartigimod iv or efgartigimod ph20 sc	ARGENX SE (ARGX)
ianalumab	Novartis AG (NVS)
Pirtobrutinib	ELI LILLY & Co (LLY)

BioSniper tracks 25 drugs in development for ITP across 16 companies.

There are 2 clinical trials targeting ITP tracked by BioSniper.

Full trial data, competitive analysis, and AI-powered pipeline tracking.